Vertex Pharmaceuticals: Buying The CF Fortress For The JOURNAVX Optionality (NASDAQ:VRTX)

Vertex Pharmaceuticals is backed by CF dominance and JOURNAVX optionality, with key catalysts ahead for growth and upside. See why VRTX stock is a buy.